The safety of magnetic resonance imaging-guided laser interstitial thermal therapy for cerebral radiation necrosis
Cerebral radiation necrosis (CRN) is a known complication of radiation therapy. Treatment options are limited and include steroids, bevacizumab, and surgery. This study seeks to determine the safety of laser interstitial thermal therapy (LITT) for CRN and identify the pattern of post-ablation volume change over time. Patients undergoing LITT for tumor treatment at Henry Ford Hospital between November 2013 and January 2016 with biopsy-confirmed CRN were prospectively collected and retrospectively reviewed with attention to ablation volume, survival, demographic data, steroid dose, and complications. Imaging occurred at set intervals beginning pre-ablation. Ten patients with 11 ablations were evaluated. Four patients had a primary diagnosis of high-grade glioma, while six had metastatic lesions. An average of 86% of CRN volume was ablated. Ablation volume increased to 430% of initial CRN volume at 1–2 weeks before decreasing to 69% after 6 months. No patient had a decline in baseline neurological examination while in the hospital. Four patients developed delayed neurological deficits likely due to post-operative edema, of which three improved back to baseline. The 6-month survival was 77.8% and the 1-year survival was 64.8% based on Kaplan–Meier curve estimates. In this study, LITT was a relatively safe treatment for CRN, providing both a diagnostic and therapeutic solution for refractory patients. Significant increase in ablation volume was noted at 1–2 months, gradually decreasing in size to less than the original volume by 6 months. Further studies are needed to better define the role of LITT in the treatment of CRN.
KeywordsLaser interstitial thermal therapy Cerebral radiation necrosis Magnetic resonance imaging-guided thermal therapy Magnetic resonance thermal imaging
This study was supported by Harris Neurosciences Grant, #H1094.
Compliance with ethical standards
Conflict of interest
Ian Lee has consulting agreements with Monteris and Visualase.
- 6.Carpentier A, McNichols RJ, Stafford RJ et al (2008) Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery 63:ONS21–ONS2128. https://doi.org/10.1227/01.neu.0000335007.07381.df; discussion ONS28-29.PubMedGoogle Scholar
- 12.Tovar-Spinoza Z, Choi H (2016) MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: a case-series review, description of the current technologies and perspectives. Childs Nerv Syst 32:1947–1956. https://doi.org/10.1007/s00381-016-3193-0 CrossRefPubMedGoogle Scholar
- 16.Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol Off J Am Soc Clin Oncol 26:2192–2197. https://doi.org/10.1200/JCO.2007.14.8163 CrossRefGoogle Scholar
- 17.Lai G, Mahadevan A, Hackney D et al (2015) Diagnostic accuracy of PET, SPECT, and arterial spin-labeling in differentiating tumor recurrence from necrosis in cerebral metastasis after stereotactic radiosurgery. AJNR Am J Neuroradiol 36:2250–2255. https://doi.org/10.3174/ajnr.A4475 CrossRefPubMedGoogle Scholar
- 18.Smith CJ, Myers CS, Chapple KM, Smith KA (2016) Long-term follow-up of 25 cases of biopsy-proven radiation necrosis or post-radiation treatment effect treated With magnetic resonance-guided laser interstitial thermal therapy. Neurosurgery 79(Suppl 1):S59–S72. https://doi.org/10.1227/NEU.0000000000001438 CrossRefPubMedGoogle Scholar